Ethical concerns about stem cell-based research have delayed important advances in many areas of medicine, including cardiology. The introduction of induced pluripotent stem cells (iPSCs) has supplanted the need to use human stem cells for most purposes, thus eliminating all ethical controversies. Since then, many new avenues have been opened in cardiology research, not only in approaches to tissue replacement but also in the design and testing of antiarrhythmic drugs. This methodology has advanced to the point where induced human cardiomyocyte cell lines can now also be obtained from commercial sources or tissue banks. Initial studies with readily available iPSCs have generally confirmed that their behavioral characteristics accurately predict the behavior of beating cardiomyocytes in vivo. As a result, iPSCs can provide new ways to study arrhythmias and heart disease in general, accelerating the development of new, more effective antiarrhythmic drugs, clinical diagnoses, and personalized medical care. The focus on producing cardiomyocytes that can be used to replace damaged heart tissue has somewhat diverted interest in a host of other applications. This manuscript is intended to provide non-specialists with a brief introduction and overview of the research carried out in the field of heart rhythm disorders.

中文翻译：

---

诱导多能干细胞在诊断心脏病学中的作用。

对基于干细胞的研究的伦理问题推迟了许多医学领域的重要进展，包括心脏病学。诱导多能干细胞 (iPSC) 的引入取代了将人类干细胞用于大多数用途的需要，从而消除了所有伦理争议。从那时起，心脏病学研究开辟了许多新途径，不仅包括组织置换方法，还包括抗心律失常药物的设计和测试。这种方法已经发展到现在也可以从商业来源或组织库中获得诱导的人类心肌细胞系。对现成的 iPSC 的初步研究普遍证实，它们的行为特征可以准确预测体内心肌细胞的跳动行为. 因此，iPSC 可以提供研究心律失常和心脏病的新方法，加速开发新的、更有效的抗心律失常药物、临床诊断和个性化医疗。对生产可用于替代受损心脏组织的心肌细胞的关注在一定程度上转移了对许多其他应用的兴趣。这份手稿旨在为非专业人士提供心律失常领域研究的简要介绍和概述。